LIVN Earnings Prediction
The chart below shows how LIVN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LIVN sees a +0.44% change in stock price 10 days leading up to the earnings, and a -3.17% change 10 days following the report. On the earnings day itself, the stock moves by +0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
LIVN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
321.83M
3.77%
1.17%
Gross Margin
68.16%
11.15%
-3.74%
Operating Margin
12.57%
232.54%
-10.79%
Net Margin
17.37%
229.60%
67.66%
EPS
1.02
240.00%
70.00%
No Data Available
LIVN Earnings Analysis
LivaNova PLC Corporation (LIVN.O) Earnings Conference Call
Positive
Double-Digit Revenue Growth: LivaNova achieved 11% organic revenue growth in 2024, marking the second consecutive year of double-digit organic growth.
Free Cash Flow Surge: The company expanded operating margins and increased free cash flow, delivering $163 million in adjusted free cash flow for the full-year 2024, a 70% increase from the previous year.
Clinical Study Success: The OSPREY clinical study for obstructive sleep apnea met its primary efficacy and safety endpoints, unlocking a strategic growth opportunity for LivaNova in a market expected to approach $2 billion by the end of the decade.
Epilepsy Revenue Growth: LivaNova's epilepsy revenue grew 7% for the full-year 2024, with U.S. epilepsy revenue increasing by 8%, driven by product mix, price, and total implants.
Cardiopulmonary Revenue Growth: The cardiopulmonary segment saw revenue growth of 14% for the full-year 2024, with expectations for continued growth in 2025 driven by the successful rollout of the Essenz product.
Innovation Pipeline Progress: The company has made significant progress in its innovation pipeline, including the launch of ProtekDuo Plus for ECMO procedures and advancements in VNS therapy for epilepsy.
Strong Operational Performance: LivaNova's adjusted operating income increased by 41% and adjusted diluted earnings per share grew by 21% in 2024, reflecting strong operational performance.
Talent Acquisition and Promotion: The company has prioritized attracting industry-leading professionals and promoting internal talent, with approximately 30% of director-level and above positions filled by new hires or promotions in 2024.
Negative
Epilepsy Segment Revenue Challenges: Revenue growth in the epilepsy segment was only 1% in Q4 2024, with a 9% decline in Europe and the rest of the world, indicating potential challenges in this market.
Earnings Per Share Decline: The adjusted diluted earnings per share decreased to $0.81 from $0.87 in Q4 2023, primarily due to a higher effective tax rate, which negatively impacted earnings.
Tax Rate Increase Impact: The company anticipates a full-year adjusted effective tax rate of approximately 24% for 2025, representing a 300 basis point increase compared to 2024, which could further pressure earnings.
Cardiopulmonary Segment Slowdown: Despite strong overall performance, the cardiopulmonary segment's growth was significantly lower than the previous year's 40% growth, indicating a potential slowdown in this area.
Litigation and Uncertain Implications: The company is facing litigation related to the SNIA matter, with a public hearing scheduled for February 26, 2025, which could have uncertain implications for the company.
Limited Epilepsy Revenue Growth: The forecast for global epilepsy revenue growth in 2025 is only 4% to 5%, suggesting limited growth potential in this segment compared to other areas.
Foreign Currency Impact on Revenue: The company expects foreign currency to be a headwind of 1.5% to 2% on revenue growth in 2025, which could negatively impact overall financial performance.
LIVN FAQs
How does LIVN typically perform around its earnings report dates?
Is LivaNova PLC (LIVN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LIVN Earning Call Sentiment
LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript
LIVN.O
1.45%Positive
The earnings report shows strong revenue growth both quarterly and annually, improved operating income, and significant free cash flow growth. However, the decrease in EPS due to a higher tax rate and increased debt from a convertible note offering are concerns. The Q&A highlighted optimism in new product launches and strategic innovations, although some execution issues were noted. Overall, the positive financial performance and promising product developments outweigh the negatives, suggesting a positive stock price movement.
